- Clover Biopharmaceuticals said its COVID-19 vaccine SCB-2019 met the main goal of a global phase 2/3 trial.
- The Chinese company added that in the trial — which enrolled 1,278 people — SCB-2019 (CpG 1018/Alum) elicited almost 2-fold higher neutralizing antibody titers in adolescents aged 12 years to 17 years, compared to young adults aged 18 years to 25 years.
- The company said that in the adults (?18 years of age), SCB-2019 had previously shown 100% efficacy in preventing severe COVID-19 and 95% efficacy against hospitalizations linked with COVID-19 at five months after vaccination.
- The vaccine showed favorable tolerability and safety profile in adolescents, consistent with what was previously seen in adults, Clover said in an Aug. 25 press release.
- The company said plans to submit this data to global regulatory agencies and seek licensure in adolescents, in addition to its ongoing submissions in China, EU and to the WHO for use in adults and elderly, to broaden potential use of SCB-2019 across age groups and as a universal COVID-19 booster vaccine.
- Clover created the COVID vaccine by combining SCB-2019 with Dynavax's ( NASDAQ: DVAX ) CpG 1018 advanced adjuvant and aluminum hydroxide (alum).
- The vaccine' development has been funded by the Coalition for Epidemic Preparedness Innovations (CEPI), which has awarded Clover up to $397.4M to enable equitable access to the vaccine candidate.
For further details see:
Clover, Dynavax COVID vaccine shows efficacy in adolescents in phase 2/3 trial